Urgent.News

What's breaking now, across thousands of outlets.

Business

Isomorphic Labs raises $5bn in ‘one of UK tech’s biggest funding rounds’

London-based AI drug discovery firm Isomorphic Labs has raised $5bn (£3.8bn) in one of the largest funding rounds in British tech, as investors bet billions on AI transforming the pharmaceutical industry. The Google Deepmind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, announced the oversubscribed Series C round on Tuesday, co-led by US venture [...]

Isomorphic Labs raises $5bn in ‘one of UK tech’s biggest funding rounds’

Isomorphic Labs, a London-based AI drug discovery company, has raised an astounding $5 billion in its largest funding round to date, solidifying its position at the forefront of transforming the pharmaceutical industry through artificial intelligence. The oversubscribed Series C round, co-led by Greenoaks and Sequoia Capital, was announced on Tuesday, with participation from notable venture capital firms Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek, and the UK government's Sovereign AI Fund.

The company, founded in 2021 and led by Nobel Prize-winning scientist Sir Demis Hassabis (from Google Deepmind), has been on a rapid growth trajectory, securing $2.1 billion in Series B funding just six months ago, bringing its total disclosed external funding to approximately $7.7 billion since 2025.

The $5 billion injection comes at a time when Isomorphic's valuation was reportedly estimated to reach up to $50 billion, a significant increase from its previous valuation of around $17.5 billion. The company remains in the late-stage preclinical development phase, with no human clinical trials conducted for its drug candidates yet.

However, Isomorphic is making significant strides in drug discovery, utilizing its proprietary AI engine, 'IsoDDE', to predict how molecules interact with biological targets and identify potential treatments for various diseases, including cancer and immune disorders. The company is also partnering with major pharmaceutical firms such as Eli Lilly, Novartis, and Johnson & Johnson, and is expanding its drug pipeline and constructing global bioengineering infrastructure to accelerate its progress towards clinical trials.

Written by urgent.news from City AM's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at cityam.com →

More in Business

More from Tuesday 17 November →